In The News

    Feed has no items.

Myeloma Research News The Web’s Daily Resource for Myeloma Research News

  • Ygalo Shows Positive Response in Triple-refractory Multiple Myeloma Trial
    by Vanessa Pataia on April 6, 2020 at 5:00 pm

    Topline results show a 26% response rate in a Phase 2 clinical trial evaluating Ygalo (melflufen) in patients with triple-refractory multiple myeloma, a difficult-to-treat form of this disease, the therapy’s developer, Oncopeptides, announced. These data will support a request for accelerated approval for Ygalo to treat people with triple-refractory multiple myeloma in the U.S., the company said in a The post Ygalo Shows Positive Response in Triple-refractory Multiple Myeloma Trial appeared first on Myeloma Research News.

  • Oncopeptides’ Accelerated Approval Filing for Ygalo in US Unimpeded by COVID-19
    by Marta Figueiredo on March 30, 2020 at 1:00 pm

    Despite some interruptions to Ygalo‘s clinical program due to the ongoing COVID-19 outbreak, Oncopeptides‘ application seeking its accelerated approval in the U.S. for the treatment of triple-refractory multiple myeloma will not be affected, and filing is expected mid-year, the company has announced. “Obviously the COVID-19 pandemic has an enormous impact on us and society as The post Oncopeptides’ Accelerated Approval Filing for Ygalo in US Unimpeded by COVID-19 appeared first on Myeloma Research News.

  • Genetic Test May Help Identify Ultra High-risk Multiple Myeloma
    by Marisa Wexler, MS on March 23, 2020 at 12:00 pm

    A novel genetic test could help identify people with multiple myeloma who are at highest risk of aggressive disease and unlikely to respond to standard treatment with Revlimid (lenalidomide), a new study shows. The study, “Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients,” was The post Genetic Test May Help Identify Ultra High-risk Multiple Myeloma appeared first on Myeloma Research News.

  • Ninlaro Combo Fails to Extend New Myeloma Patients’ Survival Without Disease Worsening
    by Iqra Mumal, MSc on March 20, 2020 at 12:00 pm

    A combination of Ninlaro (ixazomib), Revlimid (lenalidomide), and dexamethasone failed to significantly extend the time to disease progression or death in people with newly diagnosed multiple myeloma who are ineligible for stem cell transplants, compared with Revlimid and dexamethasone alone, results from a Phase 3 trial show. The combination did help patients live 13.5 months longer The post Ninlaro Combo Fails to Extend New Myeloma Patients’ Survival Without Disease Worsening appeared first on Myeloma Research News.

  • FDA Names Arcellx’s Cell Therapy CART-ddBCMA Orphan Drug for Multiple Myeloma
    by Margarida Azevedo on March 18, 2020 at 12:00 pm

    Arcellx’s CART-ddBCMA — a CAR T-cell therapy targeting the BCMA protein — was granted orphan drug status by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma. The move follows the FDA’s granting of fast track designation to the therapy for relapsed or refractory myeloma, and provides the company with various The post FDA Names Arcellx’s Cell Therapy CART-ddBCMA Orphan Drug for Multiple Myeloma appeared first on Myeloma Research News.

Myeloma Research News The Web’s Daily Resource for Myeloma Research News

  • Ygalo Shows Positive Response in Triple-refractory Multiple Myeloma Trial
    by Vanessa Pataia on April 6, 2020 at 5:00 pm

    Topline results show a 26% response rate in a Phase 2 clinical trial evaluating Ygalo (melflufen) in patients with triple-refractory multiple myeloma, a difficult-to-treat form of this disease, the therapy’s developer, Oncopeptides, announced. These data will support a request for accelerated approval for Ygalo to treat people with triple-refractory multiple myeloma in the U.S., the company said in a The post Ygalo Shows Positive Response in Triple-refractory Multiple Myeloma Trial appeared first on Myeloma Research News.

  • Oncopeptides’ Accelerated Approval Filing for Ygalo in US Unimpeded by COVID-19
    by Marta Figueiredo on March 30, 2020 at 1:00 pm

    Despite some interruptions to Ygalo‘s clinical program due to the ongoing COVID-19 outbreak, Oncopeptides‘ application seeking its accelerated approval in the U.S. for the treatment of triple-refractory multiple myeloma will not be affected, and filing is expected mid-year, the company has announced. “Obviously the COVID-19 pandemic has an enormous impact on us and society as The post Oncopeptides’ Accelerated Approval Filing for Ygalo in US Unimpeded by COVID-19 appeared first on Myeloma Research News.

  • Genetic Test May Help Identify Ultra High-risk Multiple Myeloma
    by Marisa Wexler, MS on March 23, 2020 at 12:00 pm

    A novel genetic test could help identify people with multiple myeloma who are at highest risk of aggressive disease and unlikely to respond to standard treatment with Revlimid (lenalidomide), a new study shows. The study, “Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients,” was The post Genetic Test May Help Identify Ultra High-risk Multiple Myeloma appeared first on Myeloma Research News.

  • Ninlaro Combo Fails to Extend New Myeloma Patients’ Survival Without Disease Worsening
    by Iqra Mumal, MSc on March 20, 2020 at 12:00 pm

    A combination of Ninlaro (ixazomib), Revlimid (lenalidomide), and dexamethasone failed to significantly extend the time to disease progression or death in people with newly diagnosed multiple myeloma who are ineligible for stem cell transplants, compared with Revlimid and dexamethasone alone, results from a Phase 3 trial show. The combination did help patients live 13.5 months longer The post Ninlaro Combo Fails to Extend New Myeloma Patients’ Survival Without Disease Worsening appeared first on Myeloma Research News.

  • FDA Names Arcellx’s Cell Therapy CART-ddBCMA Orphan Drug for Multiple Myeloma
    by Margarida Azevedo on March 18, 2020 at 12:00 pm

    Arcellx’s CART-ddBCMA — a CAR T-cell therapy targeting the BCMA protein — was granted orphan drug status by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma. The move follows the FDA’s granting of fast track designation to the therapy for relapsed or refractory myeloma, and provides the company with various The post FDA Names Arcellx’s Cell Therapy CART-ddBCMA Orphan Drug for Multiple Myeloma appeared first on Myeloma Research News.